Certified by Founder
Lodge
ARTBIO
start up
United States
- Cambridge, Massachusetts
- 08/12/2023
- Series A
- $90,000,000
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
- Industry Biotechnology Research
- Website https://artbio.com/
- LinkedIn https://www.linkedin.com/company/artbio-inc/
Related People
Emanuele OstuniFounder
Switzerland -
Reinach, Basel-Country
Specialties: Commercial execution, Strategy, M&A, Business Development, Entrepreneurship,
Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)